CVRx granted CE mark for the Barostim neo system for conditional MRI compatibility


CVRx has been granted CE marking to expand labelling of the Barostim neo system as safe for use in magnetic resonance imaging (MRI) systems under specified conditions. 

By enabling access to MRI scans, the expanded labelling will benefit patients receiving Barostim therapy for heart failure or resistant hypertension.

“This approval has the potential to benefit many patients and their health care providers as MRI is critical in the diagnosis of serious conditions which can occur in the populations served by Barostim therapy. We are pleased to enable access to this diagnostic option for our current and future patients,” says Nadim Yared, chief executive officer of CVRx.